Chong Feng, Shuang Song, Xiaoyu Zhang, Jing Wang, Qingxin Meng, Tao Wang
{"title":"Ultrasound-controllable carbon monoxide nano-delivery systems for combined sonodynamic/gaseous therapies.","authors":"Chong Feng, Shuang Song, Xiaoyu Zhang, Jing Wang, Qingxin Meng, Tao Wang","doi":"10.3389/fbioe.2025.1615481","DOIUrl":null,"url":null,"abstract":"<p><strong>Indroduction: </strong>The integration of sonodynamic therapy (SDT) and carbon monoxide (CO) presents a promising synergistic strategy in cancer therapy owing to the unique advantage of CO in SDT sensitization. However, the development of SDT-compatible CO-delivery nanosystems remain a substantial challenge.</p><p><strong>Methods: </strong>Here, we developed an ultrastable and controllable CO nanoreservoir system through the integration of chlorine e6 (Ce6)-loaded, cancer cell membrane coating and iron carbonyl (Fe<sub>3</sub>CO<sub>12</sub>)-bridged mesoporous silica bodies (Fe<sub>3</sub>CO<sub>12</sub>-MSNs), which was specifically engineered to simultaneously achieve SDT and ultrasound (US)-responsive sustained CO release. Owing to the stabilization of Fe<sub>3</sub>CO<sub>12</sub> within the silica framework, Fe<sub>3</sub>CO<sub>12</sub>-MSNs not only decreased unwanted CO leakage during transport but also enabled US-responsive matrix degradation accompanied by sustained CO release at tumor sites, which prolongs the therapeutic window of CO and maximizes the synergy of SDT and CO therapy.</p><p><strong>Results and discussion: </strong>This nanoplatform-mediated combination therapies showed highly efficient antitumor effects and triggered a robust tumor-specific immune responses. When in combination with immune checkpoint blockers, the nanoplatform notably eradicate the breast cancer with low systematic toxicity. Overall, our work provides a promising nanoplatform with US-responsive and sustainable CO release for highly efficient and safe SDT/CO combined therapeis.</p>","PeriodicalId":12444,"journal":{"name":"Frontiers in Bioengineering and Biotechnology","volume":"13 ","pages":"1615481"},"PeriodicalIF":4.8000,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12202442/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Bioengineering and Biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3389/fbioe.2025.1615481","RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Indroduction: The integration of sonodynamic therapy (SDT) and carbon monoxide (CO) presents a promising synergistic strategy in cancer therapy owing to the unique advantage of CO in SDT sensitization. However, the development of SDT-compatible CO-delivery nanosystems remain a substantial challenge.
Methods: Here, we developed an ultrastable and controllable CO nanoreservoir system through the integration of chlorine e6 (Ce6)-loaded, cancer cell membrane coating and iron carbonyl (Fe3CO12)-bridged mesoporous silica bodies (Fe3CO12-MSNs), which was specifically engineered to simultaneously achieve SDT and ultrasound (US)-responsive sustained CO release. Owing to the stabilization of Fe3CO12 within the silica framework, Fe3CO12-MSNs not only decreased unwanted CO leakage during transport but also enabled US-responsive matrix degradation accompanied by sustained CO release at tumor sites, which prolongs the therapeutic window of CO and maximizes the synergy of SDT and CO therapy.
Results and discussion: This nanoplatform-mediated combination therapies showed highly efficient antitumor effects and triggered a robust tumor-specific immune responses. When in combination with immune checkpoint blockers, the nanoplatform notably eradicate the breast cancer with low systematic toxicity. Overall, our work provides a promising nanoplatform with US-responsive and sustainable CO release for highly efficient and safe SDT/CO combined therapeis.
期刊介绍：
The translation of new discoveries in medicine to clinical routine has never been easy. During the second half of the last century, thanks to the progress in chemistry, biochemistry and pharmacology, we have seen the development and the application of a large number of drugs and devices aimed at the treatment of symptoms, blocking unwanted pathways and, in the case of infectious diseases, fighting the micro-organisms responsible. However, we are facing, today, a dramatic change in the therapeutic approach to pathologies and diseases. Indeed, the challenge of the present and the next decade is to fully restore the physiological status of the diseased organism and to completely regenerate tissue and organs when they are so seriously affected that treatments cannot be limited to the repression of symptoms or to the repair of damage. This is being made possible thanks to the major developments made in basic cell and molecular biology, including stem cell science, growth factor delivery, gene isolation and transfection, the advances in bioengineering and nanotechnology, including development of new biomaterials, biofabrication technologies and use of bioreactors, and the big improvements in diagnostic tools and imaging of cells, tissues and organs.
In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically apply a new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. “Frontiers in Bioengineering and Biotechnology” aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
